We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+11.92%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$191M
AUM Growth
-$59.3M
Cap. Flow
-$76.2M
Cap. Flow %
-39.78%
Top 10 Hldgs %
5.8%
Holding
489
New
53
Increased
164
Reduced
226
Closed
46

Top Buys

Rank Stock Value
1
DHI icon
D.R. Horton
DHI
+$888K
2
LEN icon
Lennar Class A
LEN
+$880K
3
MCHP icon
Microchip Technology
MCHP
+$860K
4
AME icon
Ametek
AME
+$859K
5
HD icon
Home Depot
HD
+$853K

Top Sells

Rank Stock Value
1
STLD icon
Steel Dynamics
STLD
+$1.62M
2
CQP icon
Cheniere Energy
CQP
+$1.53M
3
STOR
STORE Capital Corporation
STOR
+$1.44M
4
NOA
North American Construction
NOA
+$1.43M
5
STR
Sitio Royalties
STR
+$1.41M

Sector Composition

Rank Sector Weight
1 Healthcare 26.88%
2 Financials 12.6%
3 Technology 10.15%
4 Materials 9.55%
5 Real Estate 8.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VNDA icon
251
Vanda Pharmaceuticals
VNDA
$303M
$309K 0.16%
41,789
+16,855
+68% +$164K
RARE icon
252
Ultragenyx Pharmaceutical
RARE
$2.52B
$308K 0.16%
6,655
+1,690
+34% +$66.5K
DSU icon
253
BlackRock Debt Strategies Fund
DSU
$591M
$307K 0.16%
33,421
-6,979
-17% -$65K
ALNY icon
254
Alnylam Pharmaceuticals
ALNY
$38.7B
$307K 0.16%
1,293
-468
-27% -$99.8K
AMLX icon
255
Amylyx Pharmaceuticals
AMLX
$2.15B
$307K 0.16%
+8,307
New +$295K
BSL
256
Blackstone Senior Floating Rate 2027 Term Fund
BSL
$168M
$306K 0.16%
24,630
-2,052
-8% -$25.9K
ACAD icon
257
Acadia Pharmaceuticals
ACAD
$4.45B
$305K 0.16%
19,173
+4,680
+32% +$73.2K
ASND icon
258
Ascendis Pharma A/S
ASND
$16.7B
$304K 0.16%
2,491
-409
-14% -$47.5K
UTHR icon
259
United Therapeutics
UTHR
$25.8B
$304K 0.16%
1,093
+16
+1% +$4.04K
ITCI
260
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$303K 0.16%
5,733
+1,376
+32% +$69K
MYOV
261
DELISTED
Myovant Sciences Ltd.
MYOV
$303K 0.16%
11,251
-11,439
-50% -$301K
NBIX icon
262
Neurocrine Biosciences
NBIX
$18.2B
$303K 0.16%
2,537
-45
-2% -$5.27K
TBPH icon
263
Theravance Biopharma
TBPH
$876M
$303K 0.16%
26,989
-520
-2% -$5.46K
INSM icon
264
Insmed
INSM
$22.7B
$302K 0.16%
15,135
+1,594
+12% +$30.8K
IRWD icon
265
Ironwood Pharmaceuticals
IRWD
$604M
$302K 0.16%
24,399
+3,829
+19% +$43.4K
BBDC icon
266
Barings BDC
BBDC
$878M
$302K 0.16%
36,998
-230
-0.6% -$1.99K
EXEL icon
267
Exelixis
EXEL
$14B
$300K 0.16%
18,688
+5,361
+40% +$87.4K
IONS icon
268
Ionis Pharmaceuticals
IONS
$9.11B
$298K 0.16%
7,900
+871
+12% +$36.6K
RYTM icon
269
Rhythm Pharmaceuticals
RYTM
$7.35B
$298K 0.16%
+10,221
New +$263K
APLS
270
DELISTED
Apellis Pharmaceuticals
APLS
$297K 0.16%
5,743
-313
-5% -$16.6K
FOLD
271
DELISTED
Amicus Therapeutics
FOLD
$297K 0.15%
24,301
-5,397
-18% -$60.8K
EFR
272
Eaton Vance Senior Floating-Rate Fund
EFR
$311M
$296K 0.15%
27,087
-3,061
-10% -$34.3K
DCF
273
DELISTED
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc.
DCF
$295K 0.15%
41,751
-13,604
-25% -$97.9K
SGEN
274
DELISTED
Seagen Inc. Common Stock
SGEN
$294K 0.15%
2,291
+661
+41% +$85.3K
HALO icon
275
Halozyme
HALO
$9.87B
$294K 0.15%
5,170
-230
-4% -$11.8K
9 10
11
12 13

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2022 Portfolio in Review

As of Q4 2022, Virtus ETF Advisers held 489 positions worth $191M, down 24% from $251M the previous quarter. Its ten largest holdings account for 5.8% of the portfolio.

Virtus ETF Advisers withdrew a net $76.2M in Q4 2022, closing 46 positions and reducing 226 holdings. Its most notable exit was iShares JPMorgan USD Emerging Markets Bond ETF, an estimated $877K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 19% a quarter earlier, followed by Financials and Technology.

Against the trend, Virtus ETF Advisers opened a new position in D.R. Horton worth $987K.

  • Virtus ETF Advisers's largest Q4 2022 buy was D.R. Horton: 11,078 shares worth $987K.
  • Virtus ETF Advisers added most to Qualcomm in Q4 2022, an estimated $271K increase.
  • Virtus ETF Advisers's biggest Q4 2022 reduction was Steel Dynamics, cutting an estimated $1.62M.
  • Virtus ETF Advisers fully exited iShares JPMorgan USD Emerging Markets Bond ETF in Q4 2022, selling an estimated $877K.
  • Virtus ETF Advisers's ten largest holdings make up 5.8% of its $191M portfolio in Q4 2022.
  • Virtus ETF Advisers opened 53 new positions and closed 46 in Q4 2022.
  • Virtus ETF Advisers's portfolio value fell 24% quarter-over-quarter to $191M.

Based on Virtus ETF Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.